InvestorsHub Logo
Followers 57
Posts 5700
Boards Moderated 0
Alias Born 12/13/2004

Re: None

Thursday, 04/07/2022 6:35:55 PM

Thursday, April 07, 2022 6:35:55 PM

Post# of 14947
COVISHIELD Antibody: NEUTRALIZING ANTIBODY THERAPEUTICS...Blockbuster!

• STI-9167 developed at Sorrento in
collaboration with scientists at the
Mt. Sinai Center for Therapeutic
Antibody Development.
• STI-9167 displays potent in vivo
neutralization of SARS-CoV-2 and
Variants of Concern (VoC),
including Alpha, Beta, Gamma,
Delta, Omicron BA.1 and Omicron
BA.2
• Phase 1 clinical trials ongoing
for STI-9199 (COVISHIELD IN) in
healthy individuals and infected
patients, and planned for IV
formulation (STI-9167, COVISHIELD)
STI-9167 potently neutralizes all known
SARS-COV-2 VoCs

"The refusal of the real is the number one dogma of our time" Rene Girard

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SRNE News